Skip to content

Acceptability and Tolerance of New Oral Nutritional Supplement

Evaluation of Tolerance and Acceptability of AYMES 'LONDON' Product

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02639156
Enrollment
22
Registered
2015-12-24
Start date
2015-07-31
Completion date
2015-12-31
Last updated
2015-12-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malnutrition

Brief summary

To evaluate tolerance and acceptability of AYMES LONDON in patients requiring supplementary oral nutritional support compared with currently available alternatives.

Detailed description

TITLE EVALUATION OF TOLERANCE AND ACCEPTABILITY OF AYMES LONDON STUDY OBJECTIVES * To evaluate tolerance and acceptability of AYMES LONDON in patients requiring supplementary oral nutritional support compared with currently available alternatives. * To obtain data to support an ACBS submissions for AYMES LONDON (to allow for prescription in the community at NHS expense). STUDY DESIGN Interventional study. STUDY POPULATION 20 patients established on an oral nutritional supplement (ONS), requiring nutritional supplementation of at least 300kcal/day. Patients residing in community settings (e.g. own home, care home or community hospital) STUDY PRODUCTS AYMES LONDON Patients' current oral nutritional supplements STUDY GROUPS This is an observational study where the patient will act as their own control, there will be just one study group containing all patients STUDY OUTLINE Baseline: After recruitment patients will remain on their current oral nutritional supplement for 3 days, during which time baseline tolerance data will be recorded (number and consistency of bowel movements, daily, volume of ONS taken, any episodes of nausea, vomiting, burping, abdominal pain, bloating or diarrhoea). A three-day food diary will be kept to record total oral intake. Patients will also have anthropometric measurements carried out during this period (weight, height, body mass index (BMI)). Intervention Period : Patients will then be changed onto an equivalent prescription of AYMES LONDON for a period of 9 days. Tolerance data will be recorded daily but the first 2 days on AYMES LONDON will be considered a 'transitional' period and data from these days will not be analysed. A further 3-day food diary will be kept during the intervention period. Weight of the patient will be recorded at the end of the period on AYMES LONDON, and an acceptability questionnaire will be completed. Comparisons will be made between baseline and the end of each phase of the study using appropriate analysis methods.

Interventions

DIETARY_SUPPLEMENTAYMES LONDON

AYMES LONDON is a powder, designed to be mixed with 75ml whole milk to make a dessert style ONS. When made-up, AYMES LONDON provides 303kcal (2.2kcal/ml) and 11.2g protein. It is not designed to be used as a sole source of nutrition. It is a Food for Special Medical Purposes (FSMP) and must therefore be used under medical supervision.

Sponsors

Alison Clark Health and Nutrition
CollaboratorOTHER
Aymes International Limited
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult patients (≥18 years) who are able to communicate their views regarding acceptability. * Patients established on an oral nutritional supplement, being prescribed 1-2 ONS providing at least 300kcal/day * Patients expected to require oral nutritional supplementation for at least 2 further weeks. * Informed consent obtained

Exclusion criteria

* Participation in any other studies involving investigational or marketed products concomitantly or within two weeks prior to entry into the study * Patients requiring a milk free * Patients with medical or dietary contraindication to any feed ingredients (see appendix 2 of protocol for full list) * Patients with significant renal or hepatic impairment * Patients with dysphagia requiring stage 1,2 or 3 thickened fluids * Patients with uncontrolled inflammatory bowel disease or previous bowel resection with ongoing gastrointestinal symptoms.

Design outcomes

Primary

MeasureTime frameDescription
GI Side Effects when using AYMES LONDON9 daysRecording of any nausea, vomiting, abdominal pain, bloating / flatulence when using AYMES LONDON as assessed by presence / absence of side effect compared to baseline period

Secondary

MeasureTime frameDescription
Change to bodyweight of subjects when using AYMES LONDON9 DAYSRecording of body weight (kg) at start of study, start of intervention and end of intervention for comparison to investigate any significant weight change during the intervention period when compared to baseline.
Compliance with prescription of AYMES LONDON9 daysRecording of amount of AYMES LONDON consumed by subjects to be compared to amount prescribed of intervention period compared to baseline period.
Bowel habits of subjects when using AYMES LONDON9 daysRecording of bowel habits for one week using AYMES LONDON (as assessed by frequency and consistency of bowel movements (assessed by Bristol Stool Scale for consistency, and frequency of bowels open) compared to baseline period.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026